Kiniksa Pharmaceuticals, Ltd. (KNSA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Hamilton, Bermuda. Der aktuelle CEO ist Sanj K. Patel.
KNSA hat IPO-Datum 2018-05-25, 315 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.48B.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's product portfolio includes ARCALYST, an approved treatment for recurrent pericarditis, along with several clinical-stage candidates including Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated disorders. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is committed to addressing serious inflammatory and immunological conditions with limited existing treatment options.
